Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

See Locations Near You

Summary

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
Measurable multiple myeloma (MM)
Eastern Cooperative Oncology Group performance status of 0-1

Exclusion Criteria:

Condition that confounds the ability to interpret data from the study
Known active or history of central nervous system (CNS) involvement of MM

Note: Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

111

Study ID:

NCT06121843

Recruitment Status:

Recruiting

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States More Info
Susan Bal, Site 0008
Contact
205-934-1908
City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Myo Htut, Site 0028
Contact
626-256-4673
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States More Info
Jessica Liegel, Site 0027
Contact
617-667-9922
Local Institution - 0010
Omaha Nebraska, 68198, United States More Info
Site 0010
Contact
Laura and Isaac Perlmutter Cancer Center
New York New York, 10016, United States More Info
Jingmei Hsu, Site 0022
Contact
646-501-4848
Columbia University Irving Medical Center
New York New York, 10032, United States More Info
Divaya Bhutani, Site 0009
Contact
646-317-6303
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Sham Mailankody, Site 0012
Contact
646-608-3712
Local Institution - 0023
Pittsburgh Pennsylvania, 15232, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Krina Patel, Site 0003
Contact
713-792-6662
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

111

Study ID:

NCT06121843

Recruitment Status:

Recruiting

Sponsor:


Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider